ASR Vermogensbeheer N.V. Reduces Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• ASR Vermogensbeheer trimmed its stake in Thermo Fisher by 6.8% in Q4, selling 7,529 shares and leaving 102,662 shares worth about $59.49 million (TMO is ~0.7% of ASR’s portfolio and its 23rd-largest holding).
• Thermo Fisher beat quarterly estimates (EPS $5.44 vs. $5.25; revenue $11.01B vs. $10.86B), set FY2026 EPS guidance of 24.640–25.120, and holds a consensus Buy rating with an average price target of $623.05.
• The company raised its quarterly dividend to $0.47 (annualized $1.88, ~0.4% yield), while insiders sold roughly 5,800 shares recently and institutional ownership remains high at 89.23%.

ASR Vermogensbeheer N.V. lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.8% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 102,662 shares of the medical research company's stock after selling 7,529 shares during the period. Thermo Fisher Scientific accounts for approximately 0.7% of ASR Vermogensbeheer N.V.'s portfolio, making the stock its 23rd largest holding. ASR Vermogensbeheer N.V.'s holdings in Thermo Fisher Scientific were worth $59,488,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in TMO. Wellington Management Group LLP raised its position in shares of Thermo Fisher Scientific by 88.9% in the third quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company's stock worth $1,309,292,000 after buying an additional 1,270,191 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Thermo Fisher Scientific by 54.7% in the third quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company's stock worth $1,732,422,000 after buying an additional 1,262,967 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Thermo Fisher Scientific by 21.0% in the third quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company's stock worth $2,874,069,000 after buying an additional 1,028,125 shares in the last quarter. Corient Private Wealth LLC increased its stake in Thermo Fisher Scientific by 89.1% in the second quarter. Corient Private Wealth LLC now owns 1,752,607 shares of the medical research company's stock valued at $720,576,000 after acquiring an additional 825,649 shares during the last quarter. Finally, Capital World Investors increased its stake in Thermo Fisher Scientific by 7.4% in the third quarter. Capital World Investors now owns 10,285,145 shares of the medical research company's stock valued at $4,988,132,000 after acquiring an additional 706,572 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Up 0.1%

Shares of TMO stock opened at $473.58 on Friday. The stock has a market capitalization of $175.99 billion, a PE ratio of 26.04, a P/E/G ratio of 2.09 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99. The business has a 50-day moving average of $493.53 and a 200 day moving average of $546.70. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.19. The company had revenue of $11.01 billion during the quarter, compared to analysts' expectations of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.Thermo Fisher Scientific's quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the business posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were paid a $0.47 dividend. The ex-dividend date of this dividend was Friday, March 13th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is 10.34%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on TMO. Barclays reduced their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 14th. Morgan Stanley reissued an "overweight" rating and issued a $620.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. TD Cowen reduced their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating on the stock in a research note on Friday, January 30th. UBS Group reissued a "neutral" rating and issued a $615.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Finally, Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday, February 28th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $623.05.

Insider Activity

In related news, CEO Marc N. Casper sold 5,000 shares of the firm's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the sale, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 5,800 shares of company stock worth $2,963,544 over the last three months. 0.33% of the stock is owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.